|Drug class||Genetic enginering|
The product is designed for enhancing athletic performance and speeding up recovery both from training sessions as well as healing injuries in general. as the product causes no virilization, it can be used by women without concern. Detection by doping tests GFA-RNAst is not detectable by any standard laboratory test methods currently available anywhere in the world. Where and how the product is produced GFA-RNAst was developed and produced by Omstal Pharma, a pharmaceutical company located in Switzerland.
Systemic effect of IGF-1
Increased lipolysis (fat burning)
Supports cardiovascular function
Lowers LDL (low density lipoproteins, considered the bad cholesterol)
Has a positive effect on cartilage (improves the absorption of glucosamine and chondroitin)
Supports mental wellbeing by increasing levels of the neurotransmitter serotonin
Increases muscle mass and strength
Boosts immune system, resistance to viral infections, promotes faster recovery of the body from infectious diseases
Localized effect of IGF-1
Benefits tissue regeneration (accelerates the healing of injuries)
Localized effect of muscle growth at the injection site
Impact of CpG-motifs
Stimulates the body’s natural immunity due to CpG-motifs
Inhibits tumor growth
Reduces allergic reactions
GFA-RNAst promotes effects such as:
GFA-RNAst is an innovative product used in sports pharmacology and general medicine, being developed and produced by Omstal Pharma, a pharmaceutical company based in Switzerland.
Stimulates localized muscle growth
Quickens recovery from injuries
Boosts the immune system
Improves mental wellbeing via neurotransmitter modulation
Enhances lipolysis (fat burning)
PROVEN HIGHLY EFFECTIVE FOR LOCALIZED USE / INJECTION / ADMINISTRATION
HOW IT WORKS IN MEDICINE
Fractures, complex injuries, transnortology, burn therapy, strokes for the purpose of stimulating the growth of muscle tissue (has a greater effect than somatotropin)
Experiments on laboratory animals showed results, the technology is very promising in the treatment of various diseases of the musculoskeletal system, there are various studies and dissertations on this topic.
HOW TO USE
Intramuscular injection. 1 injection every 5 days.
COURSE OF PLASMID
The course is 40-50 days.
After this take break, as much as you took the drug.
Bodyweight up to 80 kg - 200 mcg
Bodyweight up to 100 kg - 300 mcg
Bodyweight up to 140 kg - 400 mcg
In some cases, the dosage may be increased and be individual, depending on the active cell mass. In special cases, the dosage is selected under the supervision of a specialist.
It is possible to increase efficiency if a single injection is administered not in one place at a time, but rather is “chipped” a plot of 20-50 cm2. For example, a dose of 500 mcg is divided into 5 small injections.
The injected drug does not implement itself into the cell genome, but exists alongside as an episome, separate form the genome. This mechanism indicates the safety of using plasmid DNA. Usage of GFA-RNAst has been proven to not cause mutations or elicit other negative effects on the genome.
When used, it is possible (very rarely) to raise the temperature to 37.5 (in rare cases, to 38.5) two hours after the injection. This poses no danger and is a reaction to the entry of plasmids into the cell and a reaction of immunity. Such activation of the immune system is even useful (it has an antitumor effect).
Type 2 diabetes
Store at a temperature of +2 to +8 C.
After 3-4 times freezing / thawing, it loses its properties.
The plasmid itself is quite fragile and can be damaged by strong shaking. Foam must not be allowed in the bottle.
1 year from the date of production